Skip to content

XOMA Corporation XOMA CH — Revenue

Other geography segments

US
$6.1M

Similar metrics at other companies

Monte Rosa Therapeutics, Inc. logo
GLUECH — Percentage Of Companys Revenue
22.5%-2.5pp
Bel Fuse logo
BELFBCH — Revenue
$3.94M+1.0%
IonQ logo
IONQCH — Revenue
$12.61M+625%
Constellium logo
CSTMH&C — Revenue
$2M
Organon logo
OGNChina — Revenue
$194M-4.9%
Ivanhoe Electric logo
IEChina — Revenue
$0-100%

Other financials

Income statement

See full
Revenue$12.3M-22.6%
Operating income-$480.0K-108%
Net income$4.5M+88.6%
EPS (diluted)$0.17+183%

Balance sheet

See full
Cash & equivalents$85.6M-5.2%
Total debt$124.7M+9.0%
Total equity$92.9M+9.7%
Total assets$271.9M+27.8%

Cash flow

See full
Operating cash flow$6.1M+178%
CapEx$3.0K-29.4%
Free cash flow-$2.9M+36.0%

Valuation

See full
Market cap$745.16M+159%
Enterprise value$784.29M+151%
P/E22×
P/S15.4×+8.6×

Profitability

See full
Operating margin10.2%+5.5pp
Net margin69.6%+64.0pp
FCF margin-320%-118pp

Returns & leverage

See full
Return on equity38.1%+35.2pp
Debt / equity1.3×0.0×
Current ratio3.6×-2.0×

Where this comes from

Reported directly by XOMA Corporation in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: XOMA Corporation’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about XOMA Corporation's ch — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is XOMA Corporation's CH — revenue?
XOMA Corporation (XOMA) reported CH — revenue of $6.7M in Q1 2026.
How has XOMA Corporation's CH — revenue changed year-over-year?
XOMA Corporation's CH — revenue increased by 15.1% year-over-year, from $5.82M to $6.7M.
What does CH — revenue mean?
This metric represents the total gross income generated by the company's specific business segment or asset portfolio designated as CH. It reflects the cash inflows derived from royalty interests, milestone payments, or other contractual economic rights acquired from biotechnology partners. Monitoring this revenue stream is essential for evaluating the performance and monetization success of the company's underlying therapeutic candidate investments.